Related Experiment Video
Updated: Jun 25, 2025
08:07
Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation
Published on: September 6, 2017
10.1K
Outcome-based Risk Assessment of Non-HLA Antibodies in Heart Transplantation: A Systematic Review
Anjali J Panicker1, Larry J Prokop2, Katrin Hacke3
1Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, Minnesota; Department of Immunology, Mayo Clinic, Rochester, Minnesota; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
Summary
Non-human leukocyte antigen (non-HLA) antibodies are crucial for monitoring heart transplant (HT) rejection. This review highlights their role in various rejection types, suggesting improved risk stratification beyond endomyocardial biopsies.
Area of Science:
- Immunology
- Transplant Medicine
- Clinical Pathology
Background:
- Current heart transplantation (HT) monitoring relies on invasive endomyocardial biopsies (EMB), which have limitations in predicting rejection.
- Non-human leukocyte antigen (non-HLA) antibodies are implicated in antibody-mediated rejection but are underutilized in clinical risk stratification.
- A systematic review is needed to clarify the role of non-HLA antibodies in HT rejection pathologies.
Approach:
- Searched databases for studies on non-HLA antibodies in HT recipients.
- Collected data on patient numbers, rejection types, non-HLA antigens, and associations with rejection.
- Evaluated evidence for synergistic interactions between non-HLA antibodies and donor-specific anti-human leukocyte antigen antibody (HLA-DSA) responses.
Key Points:
- Evidence for anti-MICA and anti-AT1R antibodies in HT rejection was equivocal.
- Conversely, other non-HLA antibodies show a stronger association with specific rejection pathologies.
- The strength of evidence varies for different non-HLA antibodies in mediating rejection.
Conclusions:
- Peri-transplant non-HLA antibodies are important in heart transplantation.
- Current evidence supports the involvement of non-HLA antibodies in all forms of HT rejection.
- Further research is needed to elucidate the mechanisms of non-HLA antibodies in HT rejection.
